Healthcare Business Recap: Johnson & Johnson Drops This Premature Ejaculation Drug

Achillion’s (NASDAQ:ACHN) early stage-trial hepatitis C drug ACH-3102 gets fast-track status from the FDA. This change is the same designation that the firm’s mid-stage hepatitis treatment received back in January.

Don’t Miss: Agilent Technologies Earnings: Second Straight Quarter of Rising Net Income.

The DEA has settled on a two-year suspension of Cardinal Health’s (NYSE:CAH) transferring of controlled substances from a distribution center in Florida.. The center allegedly shipped large volumes of pills to a relatively small number of pharmacies, which sparked suspicion in the DEA’s fight against the black market in pain pills.

Roche’s (RHHBY.PK) crenezumab Alzheimer’s drug may now participate in an evaluation as to whether it can be used as a preventative treatment. The trial will be carried out on an extended family in Colombia, whose approximately 5,000 members possess a gene that causes them to develop Alzheimer’s early on.

Johnson & Johnson’s (NYSE:JNJ) subsidiary Alza Corporation, along with Janssen Pharmaceutica NV, will transfer global rights for development of their premature ejaculation treatment Priligy to drug developer Furiex Pharmaceuticals (NASDAQ:FURX).

Aspects of the financial obligations of patients will be the focal point of discussions, as prominent health care and policy leaders have agreed to meet to develop a process for implementing national standards, says Accretive Health (NYSE:AH). How hospitals and other providers interact with patients regarding their financial obligations will be looked at, and new standards will be developed to cover expected charges, available resources, counseling, billing and payment procedures regardless of the ability to pay.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

Investing Insights: Did Avon Make A Huge Mistake Rejecting Coty Bid?